Conference

The start to finish of biologics

 

The Festival of Biologics brings together senior biologics professionals across the value chain to advance the industry to improve patient health.

We cover the start to finish of biologics: from discovery to development, to manufacturing and market access.

 

The European Antibody Congress is our most established event within the Festival of Biologics. Now going into its 17th year, it is Europe’s best space for discussing topics such as protein engineering, bispecifics and mAbs.

 

The World Immunotherapy Congress is your place to hear from industry leaders from companies such as Novartis, Roche and GSK. Join us in 2021 to cover themes such as Cell & Gene Therapy, Immune Check inhibitors and AI in incology.

 

Biosimilars are making their mark within the pharma industry and we are bringing together leaders to share on topics such as sustainability, innovation and biobetters and patient and physician engagement.
 

Meet our early confirmed speakers

Ana Hidalgo-Simon
Biosimilars Lead
European Medicines Agency
Ana Hidalgo-Simon speaking at Festival of Biologics Basel
Alain Beck
Senior Director, Biologics CMC and Developability, Pierre Fabre, Associate Editor
mAbs
Alain Beck speaking at Festival of Biologics Basel
Tea Gunde
Vice President Discovery
Numab
Tea Gunde speaking at Festival of Biologics Basel
Roy Baynes
Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme
Roy Baynes speaking at Festival of Biologics Basel
Samuel Pine
Head of Bioanalysis and Immunogenicity
Sanofi
Samuel Pine speaking at Festival of Biologics Basel
Federica Fraschetti
Associate Director, Large Molecules ExM, Technical Operation
Merck Sharp and Dohme
Federica Fraschetti speaking at Festival of Biologics Basel
Thomas Hach
Executive Director, Patient Engagement Cardiovascular, Renal & Metabolism
Novartis
Thomas Hach speaking at Festival of Biologics Basel
Ahuva Nissim
Professor
Queen Mary’s University London
Ahuva Nissim speaking at Festival of Biologics Basel
Martin Schiestl
Global Head of Regulatory Affairs Policy
Sandoz
Martin Schiestl speaking at Festival of Biologics Basel
Bernard Vanhove
CSO
Zenothera
Bernard Vanhove speaking at Festival of Biologics Basel
Dario Neri
CEO & CSO
Philogen
Dario Neri speaking at Festival of Biologics Basel
Stefan Zielonka
Associate Director, Protein Engineering and Antibody Technologies
Merck
Hanspeter Gerber speaking at Festival of Biologics Basel
Soraya Hölper
Project Lead for Portfolio and Strategy
Sanofi
Soraya Hölper speaking at Festival of Biologics Basel
Hans Keirstead
CEO
AVITA
Hans Keirstead speaking at Festival of Biologics Basel
Angelica Loskog
CEO
Lokon Pharmaceuticals
Angelica Loskog speaking at Festival of Biologics Basel
Sebastian Bunk
Senior Director, Pipeline Research
Immatics
Sebastian Bunk speaking at Festival of Biologics Basel
Sophia Humphreys
Director of System Pharmacy Clinical Services
Providence Healthcare Systems
Sophia Humphreys speaking at Festival of Biologics Basel
Antonella Cardone
Director
European Cancer Patient Coalition (ECPC)
Antonella Cardone speaking at Festival of Biologics Basel
Marta Baldrighi
Policy and Sciences Officer
Medicines for Europe
Marta Baldrighi speaking at Festival of Biologics Basel
Julie Marechal-Jamil
Director, Biosimilars Policy & Science
Medicines for Europe
Julie Marechal-Jamil speaking at Festival of Biologics Basel
Roger Beerli
CSO
NBE Therapeutics
Roger Beerli speaking at Festival of Biologics Basel
Daniel Muthas
Head of Data Science and Bioinformatics
AstraZeneca
Daniel Muthas speaking at Festival of Biologics Basel
Isabel del Rio
Deputy Director
BIOSIM
Isabel del Rio speaking at Festival of Biologics Basel
Jeanette Leusen
Associate Professor
UMC Utrecht
Jeanette Leusen speaking at Festival of Biologics Basel

 

BOOK TICKETS

 

Key topics on the agenda include: 

AI and Machine Learning in Oncology and Biomarkers
Antibodies in Immunotherapy
Armed Antibodies
Biosimilar Development, Manufacturing and Analysis
Biosimilars in Healthcare Policy
Checkpoint Inhibitors
Clinical Trials
CMC, Developability and Manufacturability
Commercialization and Market Access
Commercialization of Biosimilars and Sustainability of the Industry
Neoantigens
New Technology in Screening and Analytics for Antibody Proteins
Non-Oncology Immunotherapy
Novel Indications for Therapeutic Antibodies
Oncolytic Viruses
The Clinical Environment and Real-world Evidence
Tumor Microenvironment
Value and affordability of Biosimilars

 

BOOK YOUR PASS NOW